Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.

A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.

A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.

Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.

Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.